FDA’s 5-Year Plan For User Fees Gives Equal Footing To Post- And Pre-Market
This article was originally published in The Tan Sheet
Executive Summary
Over the next five years, FDA will shift its regulatory focus to ensure that the safe and effective use of drugs is of equal importance as ushering safe and effective medicines to market
You may also be interested in...
200 CDER Staff Say Goodbye To White Oak, For Now
Approximately 200 employees in FDA's Center for Drug Evaluation and Research are exiled from the agency’s White Oak campus for the next few years due to overcrowding.
200 CDER Staff Say Goodbye To White Oak, For Now
Approximately 200 employees in FDA's Center for Drug Evaluation and Research are exiled from the agency’s White Oak campus for the next few years due to overcrowding.
200 CDER Staff Say Goodbye To White Oak, For Now
Approximately 200 employees in FDA's Center for Drug Evaluation and Research are exiled from the agency’s White Oak campus for the next few years due to overcrowding.